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The traditional endpoint for assessing efficacy of chemotherapies for advanced/
recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. 
We investigated whether progression-free survival (PFS) is a valid surrogate for OS. 
Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was 
assessed through the correlation between the endpoints and through the correlation 
between the treatment effects on the endpoints. External validation of the prediction 
based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized 
trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 
(95% confidence interval [CI] = 0.852 to 0.854). The R2 between treatment effects on 
PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS 
were only moderately correlated, and we could not confirm the validity of PFS as a 
surrogate endpoint for OS in advanced/recurrent gastric cancer.
J Natl Cancer Inst;2013;105:1667–1670 
The prognosis of patients with advanced 
or recurrent gastric cancer (AGC) remains 
poor, with a 1-year median overall survival 
(OS) for commonly used chemotherapy 
regimens, consisting of fluoropyrimidine, 
platinum, taxane or anthracyclines agents 
(1). The most important issue in the devel-
opment of agents for AGC is their ability 
to prolong OS with acceptable toxicity. 
Even though median postprogression sur-
vival ranges from 5 to 10  months, a vali-
dated shorter-term surrogate endpoint 
would likely reduce drug development 
costs, sample sizes, or the duration of tri-
als aimed at establishing the benefit of new 
drugs. Progression-free survival (PFS) is 
commonly used in phase II and phase III 
trials. It has been evaluated as a surrogate 
endpoint for OS in several types of can-
cers (2–4). The ability to predict clinical 
benefits on OS from earlier benefits on 
PFS could be useful at all stages of clinical 
development. Here, we investigate the sur-
rogacy of PFS for OS within the framework 
of the GASTRIC meta-analysis (5).
Trials were eligible if they were rand-
omized, closed to accrual before the end of 
2006, and collected individual patient data 
on PFS. To explore the correlation between 
the treatment effects at the trial level, we 
relied on the comparison between the 
experimental arms of the trials included in 
the meta-analysis with their corresponding 
control arms. We defined as experimental 
the treatment that contained the larger 
number of drugs (eg, triple combinations 
vs double combinations). In case of equal 
number of drugs, we defined as experimen-
tal the treatment that included the newer 
agent. When two experimental arms were 
tested in the same trial, we combined their 
data for the purposes of the analyses. All 
data were centrally checked for inconsist-
encies (6).
We used a meta-analytic validation 
approach (3,4,7). OS was defined as the 
time from randomization to death from 
any cause or to the last follow-up. PFS was 
the time to tumor progression or death 
from any cause or time to the last follow-
up assessment. A  detailed description of 
statistical methods used is provided in the 
Supplementary Material (available online). 
For external validation, we applied the 
identified relation to predict the hazard 
ratio (HR) for OS (HROS) from the hazard 
ratio for PFS (HRPFS) in randomized trials 
published since 2000 for which we had not 
obtained the individual patient data. We 
extracted the summary statistics for both 
endpoints (8) and compared the predicted 
value of HROS to the one reported in the 
articles. To determine whether surrogacy 
also applied to other classes of agents, we 
extended the validation to three published 
trials of targeted agents (9–11).
Individual data were obtained on 4069 
patients from 20 eligible randomized tri-
als (12–30). The characteristics of the tri-
als have been described elsewhere (5). 
Thirteen trials defined the progression 
using radiological criteria, whereas seven 
used both clinical and radiological assess-
ments. Overall and at the trial level, the 
treatment effect on PFS (HR = 0.79; 95% 
confidence interval [CI]  =  0.74 to 0.85) 
tended to be larger than on OS (HR = 0.85; 
95% CI = 0.79 to 0.92) as shown on the for-
est plot of Supplementary Figures 1 and 2 
(available online).
The individual-level association, as 
measured by the rank correlation coef-
ficient, was 0.853 (95% CI  =  0.852 to 
0.854), indicating substantial correlation 
between PFS and OS for a given patient. 
The association at the trial level between 
log HROS and log HRPFS was only moder-
ate, with a coefficient of determination, R2, 
adjusted for the estimation errors (31), of 
0.61 (95% CI  =  0.04 to 1.00). The large 
confidence interval reflects the uncer-
tainty around this estimate. The linear 
regression model that relates the treat-
ment effect on PFS and on OS adjusted 
for estimations errors was
log HR 42 779 log HRS PFS0 0 0 0( ) = + × ( ). .
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where the standard errors of the intercept 
and the slope were 0.79 and 0.295, respec-
tively. This is shown as a straight line in 
Figure 1. The 95% prediction limits indicate 
the range of effect on OS that can be expected 
for a given effect on PFS. The moderate pre-
dictive accuracy at the trial level is reflected 
by the large interval width and a surrogate 
threshold effect of 0.56; hence, one should 
observe an HRPFS less than 0.56 to predict, 
with 95% probability, an HROS less than 1.
Validation on independent literature 
data (9–11,32–39) is shown in Table 1 and 
Supplementary Figure 3 (available online). 
The larger the number of progressions, 
the more precise the prediction; however, 
precision is limited by the variability of the 
regression line. The observed HROS fell 
within the prediction interval in all trials, 
even in trials using humanized monoclonal 
antibodies [Trastuzumab (10), bevaxizumab 
(9), matuzumab (11)]. However, in the trial 
that concluded a statistically significant 
benefit of trastuzumab on OS (10), the 
effect on PFS was smaller than the surro-
gate threshold effect and therefore could 
not have been used to predict a statistically 
significant effect on OS.
This is the first study based on individ-
ual patient data to evaluate whether PFS is 
a reasonable surrogate endpoint to use for 
randomized trials in AGC. Our results show 
a high correlation of PFS and OS in indi-
vidual patients but only a modest correlation 
(R2 = 0.61) between treatment effects on PFS 
and OS. It is lower than that found in trials of 
5-fluorouracil–based therapies for advanced 
colorectal cancer (4). The correlation was 
also lower than in the adjuvant setting (40).
Possible limitations that may explain the 
moderate correlation observed in our analysis 
include the numerous processes involved in 
the progression of stomach cancer (eg, local or 
distant metastasis, peritoneum involvement), 
the use of clinical and radiological assessments 
for progression, and the impact of our defi-
nition of investigational treatment related to 
the heterogeneity in chemotherapies consid-
ered here; variability in the investigated treat-
ments and in the effects of the treatments is 
a condition to generalize any results to future 
trials. Last, patients included in more recent 
trials received second-line treatments, includ-
ing crossover (30), which may have diluted 
the effect of first-line treatment on OS (2). 
Because not all trials reported the same infor-
mation at baseline, we could not assess the 
surrogacy in clinically relevant subset analyses.
All in all, we would not conclude that 
PFS is an adequate surrogate for OS in 
AGC. No precise prediction of the effect of 
a treatment on OS can be reliably drawn 
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Figure 1. Trial-level association between treatment effects. Log scale was used for the x and y axes; the horizontal line (circles) corresponds to the hazard 
ratio (HR) on overall survival of 1, which indicates the absence of effect on the overall survival. At the crossing point, the vertical line corresponds to 
the minimum amount of effect on PFS that will predict a hazard ratio on OS below 1 with 95% probability. This indicates the surrogate threshold effect.
Table 1. Observed and predicted treatment effect on overall survival, based on the observed treatment effect on progression-free survival*
Trial label Trial Observed HRPFS (95% CI) Observed HROS (95% CI) Predicted HROS (95% CI)
A Jeung et al. (36) 0.63 (0.38 to 1.05) 0.56 (0.35 to 0.88) 0.73 (0.46 to 1.04)
B AIO (33) 0.67 (0.43 to 1.04) 0.82 (0.47,1.45) 0.76 (0.53 to 1.07)
C ToGA (10) 0.71 (0.59 to 0.85) 0.74 (0.60 to 0.91) 0.80 (0.58 to 1.09)
D AVAGAST (9) 0.80 (0.68 to 0.93) 0.87 (0.73 to 1.03) 0.88 (0.76 to 1.14)
E Kang et al. (35) 0.80 (0.63 to 1.03) 0.85 (0.64 to 1.13) 0.88 (0.76 to 1.14)
F Park et al. (38) 0.86 (0.54 to 1.37) 0.96 (0.60 to 1.52) 0.93 (0.71 to 1.18)
G REAL (a)† (34) 0.92 (0.80 to 1.04) 0.92 (0.80 to 1.10) 0.98 (0.77 to 1.22)
H REAL (b) (34) 0.92 (0.81 to 1.05) 0.86 (0.80 to 0.99) 0.98 (0.77 to 1.22)
I Ross et al. (39) 0.95 (0.80 to 1.08) 0.91 (0.76 to 1.04) 1.00 (0.79 to 1.29)
J FLAGS (32) 0.99 (0.86 to 1.14) 0.92 (0.80 to 1.05) 1.03 (0.81 to 1.31)
K Rao et al. (11) 1.13 (0.63 to 2.01) 1.02 (0.61 to 1.70) 1.14 (0.89 to 1.46)
L Moehler et al. (37) 1.14 (0.59 to 2.21) 0.77 (0.51 to 1.17) 1.15 (0.90 to 1.48)
* HR = hazard ratio; PFS = progression-free survival; CI = confidence interval; OS = overall survival.
† This trial was designed as a factorial 2 × 2 plan to test two comparisons: a platinum comparison (a) and a fluoropyrimidine comparison (b).
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